Literature DB >> 16024623

Introduction of Sd(a) carbohydrate antigen in gastrointestinal cancer cells eliminates selectin ligands and inhibits metastasis.

Yuki I Kawamura1, Rei Kawashima, Ryuko Fukunaga, Kazunari Hirai, Noriko Toyama-Sorimachi, Makoto Tokuhara, Toshio Shimizu, Taeko Dohi.   

Abstract

The Sd(a) blood group carbohydrate structure is expressed in the normal gastrointestinal mucosa. We reported previously that the expression of Sd(a) carbohydrate structures and beta1,4-N-acetylgalactosaminyltransferase (beta1,4GalNAcT) activity responsible for Sd(a) synthesis were remarkably decreased in cancer lesions of the gastrointestinal tract. In this study, we found that Sd(a) antigen was expressed mainly in chief cells of normal stomach but not in cancer tissue by immunohistologic staining. In separated gastric mucosal cells, the Sd(a) glycolipids and beta1,4GalNAcT activity were concentrated in a fraction that contained chief cells as a major population. We cloned the cDNA encoding the glycosyltransferase that catalyzes the synthesis of Sd(a) (Sd(a)-beta1,4GalNAcT). Introduction of this cloned cDNA into KATO III gastric or HT29 colonic cancer cell lines, which originally expressed the E-selectin ligands, sialyl Lewis(x) and sialyl Lewis(a), resulted in a marked increase in cell-surface expression of Sd(a) along with the concomitant total loss of both sialyl Lewis(x) and sialyl Lewis(a). Both KATO III and HT29 cells transfected with the Sd(a)-beta1,4GalNAcT gene showed significantly decreased adhesion to activated human umbilical vein endothelial cells when compared with mock-transfected cells. Sd(a) determinants showed no direct binding to Siglec-3, -5, -7, and -9. These Sd(a)-beta1,4GalNAcT-transfected cells showed strikingly reduced metastatic potential in vivo when compared with mock-transfected cells. In summary, forced expression of Sd(a) carbohydrate determinant caused remarkable elimination of carbohydrate ligands for selectin and reduced metastasis of human gastrointestinal tract cancer cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16024623     DOI: 10.1158/0008-5472.CAN-05-0639

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  34 in total

1.  Comparative proteomic profiling of dystroglycan-associated proteins in wild type, mdx, and Galgt2 transgenic mouse skeletal muscle.

Authors:  Jung Hae Yoon; Eric Johnson; Rui Xu; Laura T Martin; Paul T Martin; Federica Montanaro
Journal:  J Proteome Res       Date:  2012-07-30       Impact factor: 4.466

Review 2.  Pathobiological implications of mucin glycans in cancer: Sweet poison and novel targets.

Authors:  Seema Chugh; Vinayaga S Gnanapragassam; Maneesh Jain; Satyanarayana Rachagani; Moorthy P Ponnusamy; Surinder K Batra
Journal:  Biochim Biophys Acta       Date:  2015-08-28

3.  Glycosylation of human fetal mucins: a similar repertoire of O-glycans along the intestinal tract.

Authors:  Catherine Robbe-Masselot; Emmanuel Maes; Monique Rousset; Jean-Claude Michalski; Calliope Capon
Journal:  Glycoconj J       Date:  2008-09-20       Impact factor: 2.916

4.  Human monoclonal antibodies to sialyl-Lewis (CA19.9) with potent CDC, ADCC, and antitumor activity.

Authors:  Ritsuko Sawada; Shu-Man Sun; Xiaohong Wu; Feng Hong; Govind Ragupathi; Philip O Livingston; Wolfgang W Scholz
Journal:  Clin Cancer Res       Date:  2011-02-22       Impact factor: 12.531

5.  Deletion of Galgt2 (B4Galnt2) reduces muscle growth in response to acute injury and increases muscle inflammation and pathology in dystrophin-deficient mice.

Authors:  Rui Xu; Neha Singhal; Yelda Serinagaoglu; Kumaran Chandrasekharan; Mandar Joshi; John A Bauer; Paulus M L Janssen; Paul T Martin
Journal:  Am J Pathol       Date:  2015-10       Impact factor: 4.307

6.  Soluble Heparin Binding Epidermal Growth Factor-Like Growth Factor Is a Regulator of GALGT2 Expression and GALGT2-Dependent Muscle and Neuromuscular Phenotypes.

Authors:  Megan L Cramer; Rui Xu; Paul T Martin
Journal:  Mol Cell Biol       Date:  2019-06-27       Impact factor: 4.272

7.  B4GALNT2 (GALGT2) Gene Therapy Reduces Skeletal Muscle Pathology in the FKRP P448L Mouse Model of Limb Girdle Muscular Dystrophy 2I.

Authors:  Paul J Thomas; Rui Xu; Paul T Martin
Journal:  Am J Pathol       Date:  2016-09       Impact factor: 4.307

8.  Overexpression of the cytotoxic T cell (CT) carbohydrate inhibits muscular dystrophy in the dyW mouse model of congenital muscular dystrophy 1A.

Authors:  Rui Xu; Kumaran Chandrasekharan; Jung Hae Yoon; Marybeth Camboni; Paul T Martin
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

9.  Distinct contributions of Galgt1 and Galgt2 to carbohydrate expression and function at the mouse neuromuscular junction.

Authors:  Neha Singhal; Rui Xu; Paul T Martin
Journal:  Mol Cell Neurosci       Date:  2012-09-07       Impact factor: 4.314

10.  Overexpression of Galgt2 in skeletal muscle prevents injury resulting from eccentric contractions in both mdx and wild-type mice.

Authors:  Paul T Martin; Rui Xu; Louise R Rodino-Klapac; Elaine Oglesbay; Marybeth Camboni; Chrystal L Montgomery; Kim Shontz; Louis G Chicoine; K Reed Clark; Zarife Sahenk; Jerry R Mendell; Paul M L Janssen
Journal:  Am J Physiol Cell Physiol       Date:  2008-12-24       Impact factor: 4.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.